Literature DB >> 26341758

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.

Agnese Barnabei1, Lidia Strigari2, Paolo Marchetti3, Valentina Sini4, Liana De Vecchis5, Salvatore Maria Corsello6, Francesco Torino5.   

Abstract

BACKGROUND: The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients.
MATERIALS AND METHODS: To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms "amenorrhea/chemically induced," "ovarian reserve," "anti-Mullerian hormone/blood," and "breast neoplasms/drug therapy." Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model.
RESULTS: The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602-0.904) compared with those older than 40 years (0.678; 95% CI: 0.491-0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy.
CONCLUSION: After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures. ©AlphaMed Press.

Entities:  

Keywords:  Anti-Müllerian hormone; Breast cancer; Ovarian reserve; Ovarian toxicity; Predictive factors

Mesh:

Substances:

Year:  2015        PMID: 26341758      PMCID: PMC4591948          DOI: 10.1634/theoncologist.2015-0183

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  54 in total

1.  Measuring the impact of chemotherapy on fertility in women with breast cancer.

Authors:  Kutluk Oktay; Ozgur Oktem; Andrea Reh; Linda Vahdat
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

2.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

3.  Risk of menopause during the first year after breast cancer diagnosis.

Authors:  P J Goodwin; M Ennis; K I Pritchard; M Trudeau; N Hood
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

Review 4.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

Authors:  Janice M Walshe; Neelima Denduluri; Sandra M Swain
Journal:  J Clin Oncol       Date:  2006-11-27       Impact factor: 44.544

5.  Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

Authors:  O Pagani; A O'Neill; M Castiglione; R D Gelber; A Goldhirsch; C M Rudenstam; J Lindtner; J Collins; D Crivellari; A Coates; F Cavalli; B Thürlimann; E Simoncini; M Fey; K Price; H J Senn
Journal:  Eur J Cancer       Date:  1998-04       Impact factor: 9.162

Review 6.  Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.

Authors:  J Bines; D M Oleske; M A Cobleigh
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

7.  Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography.

Authors:  W Hamish Wallace; Thomas W Kelsey
Journal:  Hum Reprod       Date:  2004-06-17       Impact factor: 6.918

8.  Effect of cytotoxic therapy on sexuality and gonadal function.

Authors:  R M Chapman
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

9.  The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer.

Authors:  R A Anderson; A P N Themmen; A Al-Qahtani; N P Groome; D A Cameron
Journal:  Hum Reprod       Date:  2006-07-04       Impact factor: 6.918

10.  Predictors of ovarian reserve in young women with breast cancer.

Authors:  K Lutchman Singh; S Muttukrishna; R C Stein; H H McGarrigle; A Patel; B Parikh; N P Groome; M C Davies; R Chatterjee
Journal:  Br J Cancer       Date:  2007-05-29       Impact factor: 7.640

View more
  6 in total

1.  Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery.

Authors:  Hyun-Ah Kim; Jihye Choi; Chan Sub Park; Min-Ki Seong; Sungeun Hong; Jae-Sung Kim; In-Chul Park; Jin Kyung Lee; Woo Chul Noh
Journal:  Endocr Connect       Date:  2018-07-16       Impact factor: 3.335

Review 2.  Fertility preservation in breast cancer with case-based examples for guidance.

Authors:  Mary E Hampe; Alice S Rhoton-Vlasak
Journal:  J Assist Reprod Genet       Date:  2020-02-01       Impact factor: 3.412

3.  ESHRE guideline: female fertility preservation.

Authors:  Richard A Anderson; Frédéric Amant; Didi Braat; Arianna D'Angelo; Susana M Chuva de Sousa Lopes; Isabelle Demeestere; Sandra Dwek; Lucy Frith; Matteo Lambertini; Caroline Maslin; Mariana Moura-Ramos; Daniela Nogueira; Kenny Rodriguez-Wallberg; Nathalie Vermeulen
Journal:  Hum Reprod Open       Date:  2020-11-14

4.  Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.

Authors:  Richard A Anderson; Tom W Kelsey; Anne Perdrix; Nathalie Olympios; Orianne Duhamel; Matteo Lambertini; Florian Clatot
Journal:  Breast Cancer Res Treat       Date:  2022-01-08       Impact factor: 4.624

5.  Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery

Authors:  Hyun-Ah Kim; Jihye Choi; Chan Su Park; Min-Ki Seong; Sung-Eun Hong; Jae-Sung Kim; In-Chul Park; Jin Kyung Lee; Woo Chul Noh
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

6.  Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

Authors:  Richard A Anderson; Rachel Remedios; Amy A Kirkwood; Pip Patrick; Linsey Stevens; Laura Clifton-Hadley; Tom Roberts; Chris Hatton; Nagesh Kalakonda; Don W Milligan; Pam McKay; Clare Rowntree; Fiona M Scott; Peter W M Johnson
Journal:  Lancet Oncol       Date:  2018-09-13       Impact factor: 54.433

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.